Log in
Enquire now
VALANX

VALANX

VALANX is a site-specific protein conjugation platform founded in 2017 by Michael Lukesch.

OverviewStructured DataIssuesContributors

Contents

valanx.bio
Is a
Company
Company
Organization
Organization

Company attributes

Industry
‌
Pharmaceutical Biology
Biomedical engineering
Biomedical engineering
Synthetic biology
Synthetic biology
Biology
Biology
Biotechnology
Biotechnology
Drug delivery
Drug delivery
...
Location
Klosterneuburg
Klosterneuburg
0
B2X
B2B
B2B
CEO
Michael Lukesch
Michael Lukesch
0
Founder
Michael Lukesch
Michael Lukesch
0
‌
Patrik Fladischer
AngelList URL
angel.co/valanx-biotech-1
Pitchbook URL
pitchbook.com/profiles...180469-81
Accelerator
RebelBio
RebelBio
Accelerator Batch
‌
RebelBio Cohort 4
Number of Employees (Ranges)
1 – 100
Full Address
Plöcking 1 IST Park Building 3400 Klosterneuburg, Austria0
Investors
Tecnet Equity
Tecnet Equity
SOSV
SOSV
Fujifilm
Fujifilm
Fondation Fournier-Majoie
Fondation Fournier-Majoie
‌
XISTA Science Ventures
‌
SkyGene
‌
Urs Spitz
Founded Date
2017
0
Total Funding Amount (USD)
5,900,000
Latest Funding Round Date
March 12, 2026
Latest Funding Type
‌
Venture round
Wellfound ID
valanx-biotech-1
Country
Austria
Austria
0
Headquarters
Vienna
Vienna

Other attributes

Blog
medium.com/@valanxbio
Company Operating Status
Active
Latest Funding Round Amount (USD)
3,500,000
No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like VALANX

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Pricing
  • Enterprise

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.